AMR Action Fund
Impact investorBoston · Seed–Series C · 13 people tracked
Investment thesis
The AMR Action Fund focuses on combating antimicrobial resistance (AMR) by investing in biotech companies developing treatments for patients suffering from life-threatening antimicrobial-resistant infections, with a stated goal of enabling 2 to 4 novel antibiotics by 2030. Beyond capital, the fund works to build partnerships that create a sustainable innovation ecosystem so new treatments continue to evolve alongside the AMR threat, and it advocates for market reforms and policy solutions that change how society values these lifesaving drugs.
Source: firm website, verified Aug 11, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 13 of 19 portfolio companiesBiotech ×13Healthtech ×6AI & Machine Learning ×2Deep Tech ×2Medical Devices ×2Digital Health ×1
HQs:United States×8Switzerland×1Spain×1United Kingdom×1
Investments · 19 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 12023 · 22022 · 12020 · 12016 · 17 dated
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections.
BiotechHealthtech
Centauri Therapeutics is an immunotherapy company developing treatments for infectious diseases and oncology using its proprietary Alphamer technology, which redirects naturally existing antibodies against life-threatening diseases.
BiotechHealthtech
BiotechArlington, US
Jon Weidanz(Director and President)Debra Weidanz(CEO and Director)
Board seatMartin Heidecker· per SEC Form D · $1.7M raise · filed Sep 2016
BiotechGaithersburg, US
Evan Loh(Director)Gregory L. Merril(Executive Officer, Director, Promoter)Jana Jensen(Director)Raymond L. Martz(Director)Carl R. Merril(Executive Officer, Director)
BoardJonathan Leff(Director)
Board seatMartin Heidecker· per SEC Form D · $30M raise · filed Jun 2023
BiotechNew York, US
Jim Flynn(Director)Kieren Marr(Executive Officer, Director)
BoardJonathan Leff(Director)
Board seatMartin Heidecker· per SEC Form D
Rgenta Therapeutics develops small molecule RNA modulation therapies through a discovery platform, aiming to create treatment options for patients with unmet medical needs across multiple therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Judith Li(Director)Debasish Roychowdhury(Director)Travis Wager(Co-founder, President and CSO)Sun Linghao(Director)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)
Board seatMartin Heidecker· per SEC Form D · $38M raise · filed Mar 2021
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)Daniel Couto(Executive Officer)Mark Mullikin(Executive Officer)Jeffrey Silber(Executive Officer)Bharatt Chowrira(Director)Christopher Viehbacher(Director)
Board seatMartin Heidecker· per SEC Form D
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
Malvern, US
Board seatMartin Heidecker· per SEC Form D
Developing a diagnostics platform using single-cell analysis and machine learning to rapidly identify bacterial pathogens and determine antibiotic susceptibility.
Peptilogics is a clinical-stage biotechnology company developing engineered peptide therapeutics, led by zaloganan (PLG0206), an anti-biofilm treatment for medical device-related infections.
BiotechHealthtechMedical DevicesPittsburg, US
Jonathan Steckbeck(Executive Officer, Director)
BoardStephan Dietrich(Director)
Telum Therapeutics is a drug discovery biotechnology company that uses synthetic biology and AI to engineer phage lytic enzymes (enzybiotics) as alternatives to traditional antibiotics.
AI & Machine LearningBiotechHealthtechNoáin, ES
BiotechRedwood City, US
Larry Kauvar(Chief Science Officer)Stefan Ryser(President and Chief Executive Officer)Geoff Dillon(Chief Business Officer)Elisabeth Whitney(Chief Operating Officer)Nora Mende(Chief Financial Officer)
PartnerJunjun Gao· ledHenry Skinner· quoted
Obtained U.S.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
IPOs and acquisitions across the tracked portfolioBiomXNYSE: PHGEUtility Therapeuticsacq. by Alembic Pharmaceuticals
Portfolio news
latest coverage across their companiesTrellis Bioscience · beckersspine.com · Jul 20, 2026
Pattern · investing.com · Jul 14, 2026
Frequently asked questions
- What stage does AMR Action Fund invest at?
- AMR Action Fund invests at the Seed, Series A, Series B, Series C stages.
- What sectors does AMR Action Fund focus on?
- AMR Action Fund focuses on Biotech, Healthtech, Impact & Social Good, Medical Devices.
- Where is AMR Action Fund located?
- AMR Action Fund is headquartered in Boston, US.
Images
Similar investors
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
Cancer Fund is an early-stage oncology venture capital and venture-giving organization that funds diagnostics, therapeutics, and other cancer-targeting innovations, offering both charitable donation and accredited-investor pathways.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
MDI Ventures is the corporate venture capital arm of Indonesia's Telkom Group, investing in technology startups and emphasizing measurable social and environmental impact alongside financial returns.